SpyGlass Pharma is trying to turn ordinary cataract surgery into lasting glaucoma therapy. The lead product mounts two non-eroding bimatoprost pads on a standard intraocular lens so a surgeon can treat pressure without changing technique or adding a separate implant. A winter public offering recapitalized the company just as two parallel registrational trials opened, and the mid-year print is the first clean look at how fast public-company spend is climbing against that cash. The debate is whether the market is paying for a follow-on drug-device that every cataract surgeon can use, or for a launch that still has to clear non-inferiority, paid reimbursement, and a live trade-secret case.
Cash and short-term investments stood at $234 million at mid-year, and management states that balance funds planned operations through the end of the decade. That cushion is real, but it is already shrinking. Second-quarter operating spend more than doubled from the year-ago period as administrative costs jumped to $11 million. Research and development rose more modestly as the company hired clinical staff rather than booked a sudden contract-research spike. The cash still covers several years of the current burn, yet the overhead step-up is the first evidence that commercial build is arriving well before any product sale.
Early clinical results are the reason the equity trades well above the offering price. In the first-in-human cohort, most patients who reached the three-year mark stayed off topical pressure drops, and the intended commercial dose in the later study produced a large mean pressure reduction with almost all evaluable patients drop-free at one year. Four-year first-in-human follow-up is due before year-end, and a first-in-human study of a ring implant for patients who already have a lens is slated for the second half. The question the next several quarters resolve is whether enrollment stays on the guided finish line while burn stays inside the cash that management already raised.